KR100603666B1 - 피라졸린 유도체, 그 제조방법 및 약으로서의 용도 - Google Patents

피라졸린 유도체, 그 제조방법 및 약으로서의 용도 Download PDF

Info

Publication number
KR100603666B1
KR100603666B1 KR1020007013447A KR20007013447A KR100603666B1 KR 100603666 B1 KR100603666 B1 KR 100603666B1 KR 1020007013447 A KR1020007013447 A KR 1020007013447A KR 20007013447 A KR20007013447 A KR 20007013447A KR 100603666 B1 KR100603666 B1 KR 100603666B1
Authority
KR
South Korea
Prior art keywords
pyrazole
dihydro
trifluoromethyl
aminosulfonylphenyl
methylsulfonylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020007013447A
Other languages
English (en)
Korean (ko)
Other versions
KR20010052437A (ko
Inventor
마리아로사 쿠베레스-알티센트
유아나마리아 베로칼-로메로
마리아몬트세라트 콘티조크-로베트
죠르디 프리골라-콘스탄사
Original Assignee
라보라토리오스 델 드라. 에스테브.에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라보라토리오스 델 드라. 에스테브.에스.에이. filed Critical 라보라토리오스 델 드라. 에스테브.에스.에이.
Publication of KR20010052437A publication Critical patent/KR20010052437A/ko
Application granted granted Critical
Publication of KR100603666B1 publication Critical patent/KR100603666B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
KR1020007013447A 1998-05-29 1999-05-27 피라졸린 유도체, 그 제조방법 및 약으로서의 용도 Expired - Fee Related KR100603666B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP9801129 1998-05-29
ES009801129A ES2137138B1 (es) 1998-05-29 1998-05-29 Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.

Publications (2)

Publication Number Publication Date
KR20010052437A KR20010052437A (ko) 2001-06-25
KR100603666B1 true KR100603666B1 (ko) 2006-07-24

Family

ID=8303969

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007013447A Expired - Fee Related KR100603666B1 (ko) 1998-05-29 1999-05-27 피라졸린 유도체, 그 제조방법 및 약으로서의 용도

Country Status (32)

Country Link
US (2) US6353117B1 (enExample)
EP (1) EP1083171B1 (enExample)
JP (1) JP4633928B2 (enExample)
KR (1) KR100603666B1 (enExample)
CN (1) CN1189459C (enExample)
AR (1) AR018402A1 (enExample)
AT (1) ATE265437T1 (enExample)
AU (1) AU752001B2 (enExample)
BG (1) BG64950B1 (enExample)
BR (1) BR9910801A (enExample)
CA (1) CA2333475C (enExample)
CO (1) CO5031241A1 (enExample)
CU (1) CU22995A3 (enExample)
CZ (1) CZ298391B6 (enExample)
DE (1) DE69916828T2 (enExample)
DK (1) DK1083171T3 (enExample)
ES (2) ES2137138B1 (enExample)
GE (1) GEP20043237B (enExample)
HU (1) HUP0102102A3 (enExample)
IS (1) IS2040B (enExample)
LT (1) LT4879B (enExample)
LV (1) LV12632B (enExample)
NO (1) NO316600B1 (enExample)
NZ (1) NZ508990A (enExample)
PL (1) PL344412A1 (enExample)
PT (1) PT1083171E (enExample)
RU (1) RU2233272C2 (enExample)
SI (1) SI20580B (enExample)
SK (1) SK285550B6 (enExample)
TW (1) TW572898B (enExample)
WO (1) WO1999062884A1 (enExample)
ZA (1) ZA200007638B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ516553A (en) 1999-06-16 2004-01-30 Univ Temple 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2 and its preparation method
DE60016191T2 (de) 1999-12-08 2005-12-22 Pharmacia Corp., Chicago Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt
ES2174757B1 (es) * 2001-04-06 2003-11-01 Esteve Labor Dr Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
US6878729B2 (en) 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
ES2183720B1 (es) 2001-06-18 2004-01-16 Esteve Labor Dr Procedimiento para la preparacion de derivados de 1,5-diaril-3-trifluorometil-delta2-pirazolinas racemicas y enantiomericamente puras.
WO2004098619A2 (en) 2003-05-07 2004-11-18 Osteologix A/S Treating cartilage / bone conditions with water-soluble strontium salts
ES2238923B1 (es) * 2004-02-16 2006-11-01 Laboratorios Del Dr. Esteve, S.A. Nuevos derivados pirazolinicos sustituidos.
US7998996B2 (en) * 2004-02-17 2011-08-16 Laboratorios Del Dr. Esteve S.A. Substituted pyrazoline compounds for reducing triglycerides in blood
ES2257929B1 (es) * 2004-07-16 2007-05-01 Laboratorios Del Dr. Esteve, S.A. Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
ES2278503B1 (es) * 2005-06-27 2008-06-16 Laboratorios Del Dr. Esteve, S.A. Epoxidacion de cetonas alfa, beta - insaturadas.
WO2007009710A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds: methods for their preparation
ES2336883B1 (es) * 2005-07-15 2011-03-22 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina sustituidos, con una estereoquimica predeterminada, para la reduccion de trigliceridos en sangre.
EP1743636A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Combination of a substituted pyrazoline compound and a drug used in food-related disorders
WO2007009703A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. New formulations of substituted pyrazoline compounds
ES2330716B1 (es) * 2005-07-15 2010-07-09 Laboratorios Del Dr.Esteve, S.A. Formulaciones farmaceuticas de compuestos de pirazolina sustituidos.
EP1743643A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. New formulations of substituted pyrazoline compounds
EP1743642A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
WO2007009698A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A Combination of pyrazoline type cannabinoid receptor antagonist and statin
EP1745781A1 (en) * 2005-07-15 2007-01-24 Laboratorios Del Dr. Esteve, S.A. Combination of pyrazoline type cannabinoid receptor antagonist and statin
EP1749526A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
EP1743638A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Pharmaceutical formulations of substituted pyrazoline compounds
ES2326725B1 (es) * 2005-07-15 2010-05-11 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos de pirazolina sustituidos para el tratamiento de trastornos alimentarios, que incluyen la obesidad o el sindrome metabolico en pacientes con diabetes desarrollada.
ES2316306B1 (es) * 2005-07-15 2009-11-23 Laboratorios Del Dr. Esteve, S.A. Combinacion de un compuesto de pirazolina sustituido y un farmaco utilizado en trastornos relacionados con los alimentos.
WO2007009692A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
EP1849784A1 (en) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Indoline-substituted pyrazoline compounds, their preparation and use as medicaments
EP1743892A1 (en) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1760078A1 (en) * 2005-07-15 2007-03-07 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds; methods for their preparation
WO2007009699A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
EP1757587A1 (en) * 2005-07-15 2007-02-28 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
WO2007009706A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
AR061623A1 (es) * 2006-06-26 2008-09-10 Novartis Ag Derivados de acido fenilacetico
US20100111858A1 (en) * 2007-01-19 2010-05-06 Howard Carol P Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands
EP3009137A1 (en) * 2014-10-16 2016-04-20 Ecuphar N.V. Pyrazoline-derived compound and its use in a weekly dosage regime against inflammation and pain derived from degenerative joint disease in mammals
EP4029502A1 (en) 2021-01-15 2022-07-20 Ecuphar N.V. Pyrazoline-derived compound (enflicoxib) for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals
CA3209491A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease
US12208085B2 (en) 2022-05-31 2025-01-28 Ecuphar Nv Pyrazoline-derived compound for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2060660B (en) * 1979-10-18 1983-11-23 Bostik Ltd Adhesives containing pyrazoline activators
JPS5818363A (ja) * 1981-07-13 1983-02-02 アメリカン・サイアナミド・カンパニ− 複素環式置換アミノピラゾリン類およびその薬としての用途
AU598633B2 (en) * 1987-01-05 1990-06-28 E.I. Du Pont De Nemours And Company 1-sub-phenyl-3-sub-phenylamino(thio) carbonyl-pyrazolines as insecticides
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
AU708964B2 (en) * 1995-05-25 1999-08-19 G.D. Searle & Co. Method of preparing 3-haloalkyl-1h-pyrazoles
GB9520584D0 (en) * 1995-10-09 1995-12-13 Fujisawa Pharmaceutical Co Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
NO20006029L (no) 2001-01-26
ES2137138A1 (es) 1999-12-01
ZA200007638B (en) 2001-11-13
BG105005A (en) 2001-08-31
DE69916828T2 (de) 2005-04-14
CZ20004418A3 (en) 2001-06-13
JP4633928B2 (ja) 2011-02-16
NO316600B1 (no) 2004-03-01
ES2137138B1 (es) 2000-09-16
LV12632A (lv) 2001-03-20
NZ508990A (en) 2002-12-20
USRE38963E1 (en) 2006-01-31
CO5031241A1 (es) 2001-04-27
EP1083171B1 (en) 2004-04-28
HUP0102102A3 (en) 2002-06-28
CA2333475C (en) 2009-12-08
TW572898B (en) 2004-01-21
PL344412A1 (en) 2001-11-05
ATE265437T1 (de) 2004-05-15
DK1083171T3 (da) 2004-08-09
IS2040B (is) 2005-08-15
CN1189459C (zh) 2005-02-16
IS5736A (is) 2000-11-28
ES2221382T3 (es) 2004-12-16
LT4879B (lt) 2002-01-25
AR018402A1 (es) 2001-11-14
WO1999062884A1 (es) 1999-12-09
RU2233272C2 (ru) 2004-07-27
LV12632B (en) 2001-07-20
AU752001B2 (en) 2002-09-05
SI20580B (sl) 2007-10-31
NO20006029D0 (no) 2000-11-28
SI20580A (sl) 2001-12-31
BR9910801A (pt) 2001-11-27
LT2000108A (en) 2001-09-25
CU22995A3 (es) 2004-10-12
CN1307566A (zh) 2001-08-08
GEP20043237B (en) 2004-05-25
AU3932999A (en) 1999-12-20
DE69916828D1 (de) 2004-06-03
HUP0102102A2 (hu) 2002-03-28
SK285550B6 (sk) 2007-03-01
BG64950B1 (bg) 2006-10-31
US6353117B1 (en) 2002-03-05
JP2002516908A (ja) 2002-06-11
KR20010052437A (ko) 2001-06-25
EP1083171A1 (en) 2001-03-14
CZ298391B6 (cs) 2007-09-19
SK18072000A3 (sk) 2001-07-10
PT1083171E (pt) 2004-09-30
CA2333475A1 (en) 1999-12-09

Similar Documents

Publication Publication Date Title
KR100603666B1 (ko) 피라졸린 유도체, 그 제조방법 및 약으로서의 용도
US5753688A (en) Substituted pyrazolyl benzenesulfonamides for the treatment of gastrointestinal conditions
US5510496A (en) Substituted pyrazolyl benzenesulfonamides
US5475018A (en) 1,5-diphenyl pyrazole compounds for treatment of inflammation
US5434178A (en) 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
EA003319B1 (ru) Производные замещенного бензолсульфонамида - пролекарства ингибиторов cox-2
KR100614600B1 (ko) 항염증성, 진통성 및 항혈전 활성을 갖는 니트록시 유도체
US20110053982A1 (en) Ether benzylidene piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors
MXPA01012903A (es) Compuestos de 5-aril-1h-1, 2, 4-triazola como inhibidores de ciclooxigenasa-2 y composiciones farmaceuticas que los contienen.
WO2009127948A1 (en) 4- [3- (aryloxy) benzylidene] -3-methyl piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors
EA022799B1 (ru) Пиразолилзамещенные производные угольной кислоты в качестве модуляторов рецептора простациклина (pgi2), применимые для лечения связанных с ним нарушений
ES2238923B1 (es) Nuevos derivados pirazolinicos sustituidos.
ES2555511T3 (es) Inhibidores de COX-2 altamente selectivos y eficaces por vía oral de 1,5-diaril-2-alquil-pirroles 3-sustituidos
MXPA00011839A (en) Pyrazoline derivatives, their preparation and application as medicaments
AU2005212833A1 (en) Pyrazoline derivatives useful for the treatment of cancer
KR840002242B1 (ko) 신규 이미다졸 화합물의 제조방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090714

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090714

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000